CSL Ltd Annual Report 2020

10. Legacy Equity Programs The following tables provide information on the key characteristics of legacy programs that were on foot during the 2020 reporting period. The 2018 (granted October 2017) and 2019 (granted September 2018) PSU LTI awards have the same key characteristics as the 2020 award disclosed in section 3.2.5. 10.1 Key Characteristics of Prior Financial Year Performance Right and Option Grants Feature 2016-2017 Grant Date 1 October 2015 (reported 2016/expiry 30 Sep 2020), 1 October 2016 (reported 2017/expiry 30 Sep 2021) Instrument Options and Performance Rights Tranches One tranche of Options and three tranches of Performance Rights Performance Period Four years Performance Measure Options – individual performance measure Performance Rights T1 – rTSR against selected global Pharmaceutical and Biotechnology companies, and T2 and T3 – EPSg Vesting Schedule Tranche 1 – rTSR < 50th %ile – 0% vesting 50th %ile – 50% vesting Between 50th and 75th %ile – Straight line vesting from 50% to 100% vesting ≥ 75th %ile – 100% vesting Tranche 2 – EPS target performance < 8% – 0% vesting 8% to 13% – Straight line vesting from 35% to 100% vesting 13% – 100% vesting Tranche 3 – EPS maximum performance 13% – 0% vesting 13% to 15% – Straight line vesting from 0% to 100% vesting 15% – 100% vesting Exercise Price Options only: 2016 – A$89.52 and 2017 – A$107.25 Retesting No retest 10.2 Key Characteristics of Prior Financial Year Executive Deferred Incentive Plan Grants Feature 2017 Grant Date 1 October 2016 (reported 2017) Instrument Notional Shares Tranches One Performance Period Three years Performance Measure Individual performance measure Vesting Schedule 100% if performance measure met Exercise Price N/A Settlement Value of the award at vest is based on the five day weighted average share price up to the award maturity date multiplied by the number of Notional Shares held Retesting No retest CSL Limited Annual Report 2020 94 Directors’ Report